mpt0e028
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2015 (NCT02350868)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Histone deacetylase 2INHIBITOR
HDAC2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 3-(1-benzenesulfonyl-2,3-dihydro-1h-indol-5-yl)-n-hydroxyacrylamide
- mpt0e028
- mpt0e028
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07244705 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2025 | Anbogen Therapeutics, Inc., Fortrea |
| NCT02350868 | Phase 1 | Jan 1, 2015 | Taipei Medical University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Anbogen Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2025 |
| Fortrea | For profit | 1 | 0 | 1 | 2025 |
| Taipei Medical University | Academic/Hospital | 1 | 1 | 1 | 2015 |
3 organizations
Page 1 / 1